Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 49 entries
Sorted by: Best Match Show Resources per page
Development and preliminary evaluation of the validity and reliability of a revised illness perception questionnaire for healthcare professionals.

BMC nursing

Arat S, Van den Zegel A, Van Rillaer M, Moons P, Vandenberghe J, De Langhe E, Westhovens R.
PMID: 27252595
BMC Nurs. 2016 Jun 01;15:34. doi: 10.1186/s12912-016-0156-4. eCollection 2016.

BACKGROUND: Diverging perceptions between individual patients with somatic diseases and their healthcare professionals might cause problems in communication and decision-making. To date, no measurement tool is available to compare the illness perceptions between these two groups. The Revised Illness...

Cite
Arat S, Van den Zegel A, Van Rillaer M, et al. Development and preliminary evaluation of the validity and reliability of a revised illness perception questionnaire for healthcare professionals. BMC Nurs. 2016;15:34doi: 10.1186/s12912-016-0156-4.
Arat, S., Van den Zegel, A., Van Rillaer, M., Moons, P., Vandenberghe, J., De Langhe, E., & Westhovens, R. (2016). Development and preliminary evaluation of the validity and reliability of a revised illness perception questionnaire for healthcare professionals. BMC nursing, 1534. https://doi.org/10.1186/s12912-016-0156-4
Arat, Seher, et al. "Development and preliminary evaluation of the validity and reliability of a revised illness perception questionnaire for healthcare professionals." BMC nursing vol. 15 (2016): 34. doi: https://doi.org/10.1186/s12912-016-0156-4
Arat S, Van den Zegel A, Van Rillaer M, Moons P, Vandenberghe J, De Langhe E, Westhovens R. Development and preliminary evaluation of the validity and reliability of a revised illness perception questionnaire for healthcare professionals. BMC Nurs. 2016 Jun 01;15:34. doi: 10.1186/s12912-016-0156-4. eCollection 2016. PMID: 27252595; PMCID: PMC4888540.
Copy Download .nbib Format: NLM
Illness representations of systemic lupus erythematosus and systemic sclerosis: a comparison of patients, their rheumatologists and their general practitioners.

Lupus science & medicine

Arat S, Lenaerts JL, De Langhe E, Verschueren P, Moons P, Vandenberghe J, Taelman V, Westhovens R.
PMID: 29177061
Lupus Sci Med. 2017 Nov 14;4(1):e000232. doi: 10.1136/lupus-2017-000232. eCollection 2017.

OBJECTIVE: Discrepancies in illness representations between patients and physicians result in treatment difficulties, decreased well-being of patients and misunderstandings and disrupted communication. Hence, the objective of this study was to compare illness perceptions of individual patients with systemic lupus...

Cite
Arat S, Lenaerts JL, De Langhe E, et al. Illness representations of systemic lupus erythematosus and systemic sclerosis: a comparison of patients, their rheumatologists and their general practitioners. Lupus Sci Med. 2017;4(1):e000232doi: 10.1136/lupus-2017-000232.
Arat, S., Lenaerts, J. L., De Langhe, E., Verschueren, P., Moons, P., Vandenberghe, J., Taelman, V., & Westhovens, R. (2017). Illness representations of systemic lupus erythematosus and systemic sclerosis: a comparison of patients, their rheumatologists and their general practitioners. Lupus science & medicine, 4(1), e000232. https://doi.org/10.1136/lupus-2017-000232
Arat, Seher, et al. "Illness representations of systemic lupus erythematosus and systemic sclerosis: a comparison of patients, their rheumatologists and their general practitioners." Lupus science & medicine vol. 4,1 (2017): e000232. doi: https://doi.org/10.1136/lupus-2017-000232
Arat S, Lenaerts JL, De Langhe E, Verschueren P, Moons P, Vandenberghe J, Taelman V, Westhovens R. Illness representations of systemic lupus erythematosus and systemic sclerosis: a comparison of patients, their rheumatologists and their general practitioners. Lupus Sci Med. 2017 Nov 14;4(1):e000232. doi: 10.1136/lupus-2017-000232. eCollection 2017. PMID: 29177061; PMCID: PMC5687554.
Copy Download .nbib Format: NLM
Identification of biomarkers of response to abatacept in patients with SLE using deconvolution of whole blood transcriptomic data from a phase IIb clinical trial.

Lupus science & medicine

Bandyopadhyay S, Connolly SE, Jabado O, Ye J, Kelly S, Maldonado MA, Westhovens R, Nash P, Merrill JT, Townsend RM.
PMID: 29214034
Lupus Sci Med. 2017 Jul 28;4(1):e000206. doi: 10.1136/lupus-2017-000206. eCollection 2017.

OBJECTIVE: To characterise patients with active SLE based on pretreatment gene expression-defined peripheral immune cell patterns and identify clusters enriched for potential responders to abatacept treatment.METHODS: This post hoc analysis used baseline peripheral whole blood transcriptomic data from patients...

Cite
Bandyopadhyay S, Connolly SE, Jabado O, et al. Identification of biomarkers of response to abatacept in patients with SLE using deconvolution of whole blood transcriptomic data from a phase IIb clinical trial. Lupus Sci Med. 2017;4(1):e000206doi: 10.1136/lupus-2017-000206.
Bandyopadhyay, S., Connolly, S. E., Jabado, O., Ye, J., Kelly, S., Maldonado, M. A., Westhovens, R., Nash, P., Merrill, J. T., & Townsend, R. M. (2017). Identification of biomarkers of response to abatacept in patients with SLE using deconvolution of whole blood transcriptomic data from a phase IIb clinical trial. Lupus science & medicine, 4(1), e000206. https://doi.org/10.1136/lupus-2017-000206
Bandyopadhyay, Somnath, et al. "Identification of biomarkers of response to abatacept in patients with SLE using deconvolution of whole blood transcriptomic data from a phase IIb clinical trial." Lupus science & medicine vol. 4,1 (2017): e000206. doi: https://doi.org/10.1136/lupus-2017-000206
Bandyopadhyay S, Connolly SE, Jabado O, Ye J, Kelly S, Maldonado MA, Westhovens R, Nash P, Merrill JT, Townsend RM. Identification of biomarkers of response to abatacept in patients with SLE using deconvolution of whole blood transcriptomic data from a phase IIb clinical trial. Lupus Sci Med. 2017 Jul 28;4(1):e000206. doi: 10.1136/lupus-2017-000206. eCollection 2017. PMID: 29214034; PMCID: PMC5704740.
Copy Download .nbib Format: NLM
The perspective of patients with early rheumatoid arthritis on the journey from symptom onset until referral to a rheumatologist.

Rheumatology advances in practice

De Cock D, Van der Elst K, Stouten V, Peerboom D, Joly J, Westhovens R, Verschueren P.
PMID: 32083241
Rheumatol Adv Pract. 2019 Aug 30;3(2):rkz035. doi: 10.1093/rap/rkz035. eCollection 2019.

OBJECTIVE: Timely treatment of patients with early RA (ERA) favours a beneficial disease outcome. However, individuals often delay their contact with a health-care professional (HCP) after ERA-related symptom onset. The aim of this study was to investigate the perspective...

Cite
De Cock D, Van der Elst K, Stouten V, et al. The perspective of patients with early rheumatoid arthritis on the journey from symptom onset until referral to a rheumatologist. Rheumatol Adv Pract. 2019;3(2):rkz035doi: 10.1093/rap/rkz035.
De Cock, D., Van der Elst, K., Stouten, V., Peerboom, D., Joly, J., Westhovens, R., & Verschueren, P. (2019). The perspective of patients with early rheumatoid arthritis on the journey from symptom onset until referral to a rheumatologist. Rheumatology advances in practice, 3(2), rkz035. https://doi.org/10.1093/rap/rkz035
De Cock, Diederik, et al. "The perspective of patients with early rheumatoid arthritis on the journey from symptom onset until referral to a rheumatologist." Rheumatology advances in practice vol. 3,2 (2019): rkz035. doi: https://doi.org/10.1093/rap/rkz035
De Cock D, Van der Elst K, Stouten V, Peerboom D, Joly J, Westhovens R, Verschueren P. The perspective of patients with early rheumatoid arthritis on the journey from symptom onset until referral to a rheumatologist. Rheumatol Adv Pract. 2019 Aug 30;3(2):rkz035. doi: 10.1093/rap/rkz035. eCollection 2019. PMID: 32083241; PMCID: PMC7018614.
Copy Download .nbib Format: NLM
Foreword from the judges.

Rheumatology advances in practice

Tan AL, Westhovens R, Ndosi M.
PMID: 34755029
Rheumatol Adv Pract. 2021 Nov 05;5:iia. doi: 10.1093/rap/rkab080. eCollection 2021 Nov.

No abstract available.

Cite
Tan AL, Westhovens R, Ndosi M. Foreword from the judges. Rheumatol Adv Pract. 2021;5:iiadoi: 10.1093/rap/rkab080.
Tan, A. L., Westhovens, R., & Ndosi, M. (2021). Foreword from the judges. Rheumatology advances in practice, 5iia. https://doi.org/10.1093/rap/rkab080
Tan, Ai Lyn, et al. "Foreword from the judges." Rheumatology advances in practice vol. 5 (2021): iia. doi: https://doi.org/10.1093/rap/rkab080
Tan AL, Westhovens R, Ndosi M. Foreword from the judges. Rheumatol Adv Pract. 2021 Nov 05;5:iia. doi: 10.1093/rap/rkab080. eCollection 2021 Nov. PMID: 34755029; PMCID: PMC8570144.
Copy Download .nbib Format: NLM
Filgotinib in combination with methotrexate or as monotherapy versus methotrexate monotherapy in patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: the phase 3, randomised controlled FINCH 3 trial.

Annals of the rheumatic diseases

Westhovens R, Rigby WFC, van der Heijde D, Ching DWT, Stohl W, Kay J, Chopra A, Bartok B, Matzkies F, Yin Z, Guo Y, Tasset C, Sundy JS, Jahreis A, Mozaffarian N, Messina OD, Landewé RB, Atsumi T, Burmester GR.
PMID: 33452004
Ann Rheum Dis. 2021 Jan 15; doi: 10.1136/annrheumdis-2020-219213. Epub 2021 Jan 15.

OBJECTIVES: To investigate efficacy and safety of the Janus kinase-1 inhibitor filgotinib in patients with active rheumatoid arthritis (RA) with limited or no prior methotrexate (MTX) exposure.METHODS: This 52-week, phase 3, multicentre, double-blind clinical trial (NCT02886728) evaluated once-daily oral...

Cite
Westhovens R, Rigby WFC, van der Heijde D, et al. Filgotinib in combination with methotrexate or as monotherapy versus methotrexate monotherapy in patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: the phase 3, randomised controlled FINCH 3 trial. Ann Rheum Dis. 2021;doi: 10.1136/annrheumdis-2020-219213.
Westhovens, R., Rigby, W. F. C., van der Heijde, D., Ching, D. W. T., Stohl, W., Kay, J., Chopra, A., Bartok, B., Matzkies, F., Yin, Z., Guo, Y., Tasset, C., Sundy, J. S., Jahreis, A., Mozaffarian, N., Messina, O. D., Landewé, R. B., Atsumi, T., & Burmester, G. R. (2021). Filgotinib in combination with methotrexate or as monotherapy versus methotrexate monotherapy in patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: the phase 3, randomised controlled FINCH 3 trial. Annals of the rheumatic diseases, . https://doi.org/10.1136/annrheumdis-2020-219213
Westhovens, René, et al. "Filgotinib in combination with methotrexate or as monotherapy versus methotrexate monotherapy in patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: the phase 3, randomised controlled FINCH 3 trial." Annals of the rheumatic diseases vol. (2021). doi: https://doi.org/10.1136/annrheumdis-2020-219213
Westhovens R, Rigby WFC, van der Heijde D, Ching DWT, Stohl W, Kay J, Chopra A, Bartok B, Matzkies F, Yin Z, Guo Y, Tasset C, Sundy JS, Jahreis A, Mozaffarian N, Messina OD, Landewé RB, Atsumi T, Burmester GR. Filgotinib in combination with methotrexate or as monotherapy versus methotrexate monotherapy in patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: the phase 3, randomised controlled FINCH 3 trial. Ann Rheum Dis. 2021 Jan 15; doi: 10.1136/annrheumdis-2020-219213. Epub 2021 Jan 15. PMID: 33452004; PMCID: PMC8142453.
Copy Download .nbib Format: NLM
Intravenous pegylated liposomal prednisolone outperforms intramuscular methylprednisolone in treating rheumatoid arthritis flares: A randomized controlled clinical trial.

Journal of controlled release : official journal of the Controlled Release Society

Metselaar JM, Middelink LM, Wortel CH, Bos R, van Laar JM, Vonkeman HE, Westhovens R, Lammers T, Yao SL, Kothekar M, Raut A, Bijlsma JWJ.
PMID: 34896445
J Control Release. 2021 Dec 10;341:548-554. doi: 10.1016/j.jconrel.2021.12.007. Epub 2021 Dec 10.

Glucocorticoids (GCs) are potent anti-inflammatory drugs but their use is limited by systemic exposure leading to toxicity. Targeted GC delivery to sites of inflammation via encapsulation in long-circulating liposomes may improve the therapeutic index. We performed a randomized, double-blind,...

Cite
Metselaar JM, Middelink LM, Wortel CH, et al. Intravenous pegylated liposomal prednisolone outperforms intramuscular methylprednisolone in treating rheumatoid arthritis flares: A randomized controlled clinical trial. J Control Release. 2021;341:548-554doi: 10.1016/j.jconrel.2021.12.007.
Metselaar, J. M., Middelink, L. M., Wortel, C. H., Bos, R., van Laar, J. M., Vonkeman, H. E., Westhovens, R., Lammers, T., Yao, S. L., Kothekar, M., Raut, A., & Bijlsma, J. W. J. (2021). Intravenous pegylated liposomal prednisolone outperforms intramuscular methylprednisolone in treating rheumatoid arthritis flares: A randomized controlled clinical trial. Journal of controlled release : official journal of the Controlled Release Society, 341548-554. https://doi.org/10.1016/j.jconrel.2021.12.007
Metselaar, Josbert M, et al. "Intravenous pegylated liposomal prednisolone outperforms intramuscular methylprednisolone in treating rheumatoid arthritis flares: A randomized controlled clinical trial." Journal of controlled release : official journal of the Controlled Release Society vol. 341 (2021): 548-554. doi: https://doi.org/10.1016/j.jconrel.2021.12.007
Metselaar JM, Middelink LM, Wortel CH, Bos R, van Laar JM, Vonkeman HE, Westhovens R, Lammers T, Yao SL, Kothekar M, Raut A, Bijlsma JWJ. Intravenous pegylated liposomal prednisolone outperforms intramuscular methylprednisolone in treating rheumatoid arthritis flares: A randomized controlled clinical trial. J Control Release. 2021 Dec 10;341:548-554. doi: 10.1016/j.jconrel.2021.12.007. Epub 2021 Dec 10. PMID: 34896445.
Copy Download .nbib Format: NLM
Five-year treat-to-target outcomes after methotrexate induction therapy with or without other csDMARDs and temporary glucocorticoids for rheumatoid arthritis in the CareRA trial.

Annals of the rheumatic diseases

Stouten V, Westhovens R, Pazmino S, De Cock D, Van der Elst K, Joly J, Bertrand D, Verschueren P.
PMID: 33811036
Ann Rheum Dis. 2021 Apr 02; doi: 10.1136/annrheumdis-2020-219825. Epub 2021 Apr 02.

OBJECTIVES: To compare outcomes of different treatment schedules from the care in early rheumatoid arthritis (CareRA) trial over 5 years.METHODS: Patients with RA completing the 2-year CareRA randomised controlled trial were eligible for the 3-year observational CareRA-plus study. 5-year...

Cite
Stouten V, Westhovens R, Pazmino S, et al. Five-year treat-to-target outcomes after methotrexate induction therapy with or without other csDMARDs and temporary glucocorticoids for rheumatoid arthritis in the CareRA trial. Ann Rheum Dis. 2021;doi: 10.1136/annrheumdis-2020-219825.
Stouten, V., Westhovens, R., Pazmino, S., De Cock, D., Van der Elst, K., Joly, J., Bertrand, D., & Verschueren, P. (2021). Five-year treat-to-target outcomes after methotrexate induction therapy with or without other csDMARDs and temporary glucocorticoids for rheumatoid arthritis in the CareRA trial. Annals of the rheumatic diseases, . https://doi.org/10.1136/annrheumdis-2020-219825
Stouten, Veerle, et al. "Five-year treat-to-target outcomes after methotrexate induction therapy with or without other csDMARDs and temporary glucocorticoids for rheumatoid arthritis in the CareRA trial." Annals of the rheumatic diseases vol. (2021). doi: https://doi.org/10.1136/annrheumdis-2020-219825
Stouten V, Westhovens R, Pazmino S, De Cock D, Van der Elst K, Joly J, Bertrand D, Verschueren P. Five-year treat-to-target outcomes after methotrexate induction therapy with or without other csDMARDs and temporary glucocorticoids for rheumatoid arthritis in the CareRA trial. Ann Rheum Dis. 2021 Apr 02; doi: 10.1136/annrheumdis-2020-219825. Epub 2021 Apr 02. PMID: 33811036.
Copy Download .nbib Format: NLM
Efficacy and safety of filgotinib alone and in combination with methotrexate in Japanese patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: Subpopulation analyses of 24-week data of a global phase 3 study (FINCH 3).

Modern rheumatology

Atsumi T, Tanaka Y, Matsubara T, Amano K, Ishiguro N, Sugiyama E, Yamaoka K, Westhovens R, Ching DWT, Messina OD, Burmester GR, Bartok B, Pechonkina A, Kondo A, Yin Z, Guo Y, Tasset C, Sundy JS, Takeuchi T.
PMID: 34910203
Mod Rheumatol. 2021 Oct 07; doi: 10.1093/mr/roab021. Epub 2021 Oct 07.

OBJECTIVES: To evaluate the efficacy and safety of filgotinib for Japanese patients with rheumatoid arthritis (RA) and limited or no prior methotrexate (MTX) exposure.METHODS: Data up to 24 weeks were analysed for 71 Japanese patients from a 52-week global...

Cite
Atsumi T, Tanaka Y, Matsubara T, et al. Efficacy and safety of filgotinib alone and in combination with methotrexate in Japanese patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: Subpopulation analyses of 24-week data of a global phase 3 study (FINCH 3). Mod Rheumatol. 2021;doi: 10.1093/mr/roab021.
Atsumi, T., Tanaka, Y., Matsubara, T., Amano, K., Ishiguro, N., Sugiyama, E., Yamaoka, K., Westhovens, R., Ching, D. W. T., Messina, O. D., Burmester, G. R., Bartok, B., Pechonkina, A., Kondo, A., Yin, Z., Guo, Y., Tasset, C., Sundy, J. S., & Takeuchi, T. (2021). Efficacy and safety of filgotinib alone and in combination with methotrexate in Japanese patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: Subpopulation analyses of 24-week data of a global phase 3 study (FINCH 3). Modern rheumatology, . https://doi.org/10.1093/mr/roab021
Atsumi, Tatsuya, et al. "Efficacy and safety of filgotinib alone and in combination with methotrexate in Japanese patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: Subpopulation analyses of 24-week data of a global phase 3 study (FINCH 3)." Modern rheumatology vol. (2021). doi: https://doi.org/10.1093/mr/roab021
Atsumi T, Tanaka Y, Matsubara T, Amano K, Ishiguro N, Sugiyama E, Yamaoka K, Westhovens R, Ching DWT, Messina OD, Burmester GR, Bartok B, Pechonkina A, Kondo A, Yin Z, Guo Y, Tasset C, Sundy JS, Takeuchi T. Efficacy and safety of filgotinib alone and in combination with methotrexate in Japanese patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: Subpopulation analyses of 24-week data of a global phase 3 study (FINCH 3). Mod Rheumatol. 2021 Oct 07; doi: 10.1093/mr/roab021. Epub 2021 Oct 07. PMID: 34910203.
Copy Download .nbib Format: NLM
A Review of Persuasive Principles in Mobile Apps for Chronic Arthritis Patients: Opportunities for Improvement.

JMIR mHealth and uHealth

Geuens J, Swinnen TW, Westhovens R, de Vlam K, Geurts L, Vanden Abeele V.
PMID: 27742604
JMIR Mhealth Uhealth. 2016 Oct 13;4(4):e118. doi: 10.2196/mhealth.6286.

BACKGROUND: Chronic arthritis (CA), an umbrella term for inflammatory rheumatic and other musculoskeletal diseases, is highly prevalent. Effective disease-modifying antirheumatic drugs for CA are available, with the exception of osteoarthritis, but require a long-term commitment of patients to comply...

Cite
Geuens J, Swinnen TW, Westhovens R, et al. A Review of Persuasive Principles in Mobile Apps for Chronic Arthritis Patients: Opportunities for Improvement. JMIR Mhealth Uhealth. 2016;4(4):e118doi: 10.2196/mhealth.6286.
Geuens, J., Swinnen, T. W., Westhovens, R., de Vlam, K., Geurts, L., & Vanden Abeele, V. (2016). A Review of Persuasive Principles in Mobile Apps for Chronic Arthritis Patients: Opportunities for Improvement. JMIR mHealth and uHealth, 4(4), e118. https://doi.org/10.2196/mhealth.6286
Geuens, Jonas, et al. "A Review of Persuasive Principles in Mobile Apps for Chronic Arthritis Patients: Opportunities for Improvement." JMIR mHealth and uHealth vol. 4,4 (2016): e118. doi: https://doi.org/10.2196/mhealth.6286
Geuens J, Swinnen TW, Westhovens R, de Vlam K, Geurts L, Vanden Abeele V. A Review of Persuasive Principles in Mobile Apps for Chronic Arthritis Patients: Opportunities for Improvement. JMIR Mhealth Uhealth. 2016 Oct 13;4(4):e118. doi: 10.2196/mhealth.6286. PMID: 27742604; PMCID: PMC5083846.
Copy Download .nbib Format: NLM
Perspectives on Subcutaneous Infliximab for Rheumatic Diseases and Inflammatory Bowel Disease: Before, During, and After the COVID-19 Era.

Advances in therapy

Schreiber S, Ben-Horin S, Alten R, Westhovens R, Peyrin-Biroulet L, Danese S, Hibi T, Takeuchi K, Magro F, An Y, Kim DH, Yoon S, Reinisch W.
PMID: 34988877
Adv Ther. 2022 Jan 06; doi: 10.1007/s12325-021-01990-6. Epub 2022 Jan 06.

The coronavirus disease 2019 (COVID-19) pandemic has prompted significant changes in patient care in rheumatology and gastroenterology, with clinical guidance issued to manage ongoing therapy while minimising the risk of nosocomial infection for patients and healthcare professionals (HCPs). Subcutaneous...

Cite
Schreiber S, Ben-Horin S, Alten R, et al. Perspectives on Subcutaneous Infliximab for Rheumatic Diseases and Inflammatory Bowel Disease: Before, During, and After the COVID-19 Era. Adv Ther. 2022;doi: 10.1007/s12325-021-01990-6.
Schreiber, S., Ben-Horin, S., Alten, R., Westhovens, R., Peyrin-Biroulet, L., Danese, S., Hibi, T., Takeuchi, K., Magro, F., An, Y., Kim, D. H., Yoon, S., & Reinisch, W. (2022). Perspectives on Subcutaneous Infliximab for Rheumatic Diseases and Inflammatory Bowel Disease: Before, During, and After the COVID-19 Era. Advances in therapy, . https://doi.org/10.1007/s12325-021-01990-6
Schreiber, Stefan, et al. "Perspectives on Subcutaneous Infliximab for Rheumatic Diseases and Inflammatory Bowel Disease: Before, During, and After the COVID-19 Era." Advances in therapy vol. (2022). doi: https://doi.org/10.1007/s12325-021-01990-6
Schreiber S, Ben-Horin S, Alten R, Westhovens R, Peyrin-Biroulet L, Danese S, Hibi T, Takeuchi K, Magro F, An Y, Kim DH, Yoon S, Reinisch W. Perspectives on Subcutaneous Infliximab for Rheumatic Diseases and Inflammatory Bowel Disease: Before, During, and After the COVID-19 Era. Adv Ther. 2022 Jan 06; doi: 10.1007/s12325-021-01990-6. Epub 2022 Jan 06. PMID: 34988877.
Copy Download .nbib Format: NLM
Titre-specific positive predictive value of antinuclear antibody patterns.

Annals of the rheumatic diseases

Vulsteke JB, Van Hoovels L, Willems P, Vander Cruyssen B, Vanderschueren S, Westhovens R, Blockmans D, De Langhe E, Bossuyt X.
PMID: 31601627
Ann Rheum Dis. 2019 Oct 10; doi: 10.1136/annrheumdis-2019-216245. Epub 2019 Oct 10.

No abstract available.

Cite
Vulsteke JB, Van Hoovels L, Willems P, et al. Titre-specific positive predictive value of antinuclear antibody patterns. Ann Rheum Dis. 2019;doi: 10.1136/annrheumdis-2019-216245.
Vulsteke, J. B., Van Hoovels, L., Willems, P., Vander Cruyssen, B., Vanderschueren, S., Westhovens, R., Blockmans, D., De Langhe, E., & Bossuyt, X. (2019). Titre-specific positive predictive value of antinuclear antibody patterns. Annals of the rheumatic diseases, . https://doi.org/10.1136/annrheumdis-2019-216245
Vulsteke, Jean-Baptiste, et al. "Titre-specific positive predictive value of antinuclear antibody patterns." Annals of the rheumatic diseases vol. (2019). doi: https://doi.org/10.1136/annrheumdis-2019-216245
Vulsteke JB, Van Hoovels L, Willems P, Vander Cruyssen B, Vanderschueren S, Westhovens R, Blockmans D, De Langhe E, Bossuyt X. Titre-specific positive predictive value of antinuclear antibody patterns. Ann Rheum Dis. 2019 Oct 10; doi: 10.1136/annrheumdis-2019-216245. Epub 2019 Oct 10. PMID: 31601627.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 49 entries